ArticleAlzheimer's & dementia (Amsterdam, Netherlands)
Association of cancer with neuropathological markers of Alzheimer's disease and related dementias.
Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting the crosstalk between Alzheimer's disease and gastrointestinal cancers.Molecular medicine (Cambridge, Mass.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWe assessed associations of cancer diagnoses with neuropathology of Alzheimer's disease (AD) and related dementias.
methodsWe retrieved 2288 cases from the National Alzheimer Coordinating Center (NACC) cohort with available information on cancer diagnoses and neuropathological scoring of Braak stages, Thal amyloid phases, neuritic plaques, TDP-43 pathology, and Lewy body pathology. We used Bayesian ordinal regression to assess associations of prevalent or incident cancer diagnoses with global cognition and postmortem neuropathological scores.
resultsWe found extreme evidence (Bayes factor [BF] > 2000) that both prevalent and incident cancer diagnoses were associated with better global cognition, strong evidence (BF = 26) for an association of a prevalent cancer diagnosis with lower TDP-43 pathology, and weak evidence (BF = 3.2) for an association with lower Lewy body pathology. DISCUSSION: Our data suggest that selective survival and biological effects may contribute to the lower risk of dementia in people with a cancer diagnosis. Highlights: A prevalent diagnosis of cancer was associated with a lower risk of cognitive decline in older individuals.A prevalent diagnosis of cancer was associated with a lower risk of TDP-43 pathology and Lewy body pathology in older individuals.Effects of cancer on TDP-43 pathology were maintained when controlling for degree of cognitive decline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.